"Samsung Electronics to Achieve 100 Trillion Won in Operating Profit Next Year, Shares Severely Undervalued"... LG Energy Solution's Target Price Cut After Ford Contract Cancellation [Zootopia]

[Financial News] Here is a summary of major securities firm reports as of the morning of December 18.
Samsung Electronics is on track to achieve 100 trillion won in operating profit next year, driven by rising prices of HBM and standard DRAM. LG Energy Solution saw its target price lowered after its large-scale battery supply contract with Ford Motor Company was canceled. Hanmi Pharmaceutical's target price was significantly raised after the successful domestic phase 3 trial of its independently developed GLP-1 class obesity treatment.
◆Samsung Electronics (005930)― KB Securities / Kim Dong-won, Head of Research
- Target price: 160,000 won
- Investment opinion: Buy
KB Securities stated that Samsung Electronics is poised to benefit the most from rising prices of HBM and standard DRAM, making the achievement of 100 trillion won in operating profit next year increasingly likely. Kim Dong-won, Head of Research, projected that Samsung Electronics' HBM market share will double from 16% this year to 35% next year. He also noted that the current share price is trading at a 43% discount compared to competitors, suggesting a revaluation phase is imminent.
◆LG Energy Solution (373220)― Samsung Securities / Cho Hyun-ryeol, Analyst
- Target price: 480,000 won (revised down from 550,000 won)
- Investment opinion: Hold
Samsung Securities predicted that LG Energy Solution will inevitably see a decline in sales after 2027 due to the cancellation of a 9.6 trillion won battery supply contract with Ford Motor Company. Analyst Cho Hyun-ryeol explained that securing new orders immediately after the contract cancellation will be challenging, making it unavoidable for the improvement in European plant utilization in 2027 to be delayed. Accordingly, the target price was lowered from 550,000 won to 480,000 won.
◆Hanmi Pharmaceutical (128940)― HYUNDAI MOTOR SECURITIES / Yeo No-rae, Analyst
- Target price: 550,000 won (raised from 400,000 won)
- Investment opinion: Buy
HYUNDAI MOTOR SECURITIES expects Hanmi Pharmaceutical's obesity drug 'efpeglenatide' to increase its non-operating value after demonstrating weight loss efficacy and safety at 40 weeks in domestic phase 3 clinical trials. Analyst Yeo No-rae stated that the success of the phase 3 trial led to a revision of the risk discount rate, raising the non-operating value from 369.9 billion won to 1.141 trillion won, and the target price was adjusted upward from 400,000 won to 550,000 won.

sms@fnnews.com Seong Min-seo Reporter